{{--
  Back to User
--}}
{{ $DoctorName }} @if (isset(session()->get('doctor')['vCentralCode'])) {{ session()->get('doctor')['vCentralCode'] }} @endif
@if (isset(session()->get('doctor')['vCentralCode'])) Logout @endif

{{ $ActivityTypeName }}

{{ $ActivityName }}

@csrf
Back

A survey to assess the anti-diabetic drug choices in T2D patients with or without complications (Amplify)

Doctor's details
@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

@if (isset(session()->get('doctor')['vCentralCode']))
@else
@endif

  1. What are the factors considered for screening a patient for diabetes? *
  2. Do you consider screening for diabetes in patients with ASCVD or renal impairment? *

  3. What are the investigations considered for screening patients for diabetes? *
  4. Do you consider screening for ASCVD in diabetic patients? *

  5. What are the investigations considered for screening patients for ASCVD? *
  6. What is your preferred diabetic therapy in patients with ASCVD? *
  7. Do you consider screening for renal impairment in diabetic patients? *

  8. What are the investigations considered for screening patients for renal impairment? *
  9. What is your preferred diabetic therapy in patients with renal impairment? *
  10. Do you consider screening for albuminuria in diabetic patients with normal eGFR? *

  11. Do you consider screening for albuminuria in diabetic patients with abnormal eGFR? *

  12. Which investigations do you consider to screen for albuminuria? *
  13. What is your preferred diabetic therapy in patients with albuminuria with or without abnormal eGFR? *
  14. Do you consider screening for heart failure in diabetic patients? *

  15. Which investigations do you consider to screen for heart failure in diabetic patients? *
  16. What is your preferred diabetic therapy in patients with heart failure with preserved ejection fraction?*
  17. What is your preferred diabetic therapy in patients with heart failure with reduced ejection fraction? *
  18. What is your preferred diabetic therapy in patients with heart failure with mildly reduced ejection fraction? *
  19. Do you consider initiating therapy in patients with left ventricular diastolic dysfunction? *

  20. What is your preferred diabetic therapy in patients with left ventricular diastolic dysfunction? *
  21. What percentage of diabetic patients have cardiac renal and metabolic disorders? *

  22. Which drugs do you consider have an effect on all cardiac renal and metabolic disorders? *

  23. Which drugs do you consider patients with heart failure with mildly reduced ejection fraction? *

  24. What percentage of your diabetic patients on treatment over a year have a HBa1c <7% ? *

  25. What are the factors inhibit achieving a HbA1c of <7%? *
  26. Do you consider continuing dapagliflozin in diabetic patients with renal impairment? *

  27. Which combination of dapagliflozin do you consider for patients with HbA1c >7.5%? *

  28. Which combination of dapagliflozin do you consider for patients with HbA1c >8.5%? *

  29. Which combination of dapagliflozin do you consider for patients with HbA1c >10.0%? *

  30. Which combination of dapagliflozin do you consider for patients with diabetes and ASCVD? *

  31. Which combination of dapagliflozin do you consider for patients with diabetes and renal impairment? *

  32. Which combination of dapagliflozin do you consider for patients with diabetes and Heart failure? *

  33. In which patient profiles do you consider dapagliflozin? *
  34. When do you consider stopping dapagliflozin? *

  35. In which patients’ profiles do you consider dapagliflozin combinations *